LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

0.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.5

Max

0.59

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+885.11% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-448M 99M
Eelmine avamishind	0.51
Eelmine sulgemishind	0.51

Uudiste sentiment

By Acuity

94%

333 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. märts 2026, 23:39 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4. märts 2026, 23:20 UTC

Tulu

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4. märts 2026, 21:43 UTC

Tulu

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4. märts 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy 4Q EPS C$2.86 >VET

4. märts 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Rev $66.8M >LAC

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Loss/Shr 52c >LAC

4. märts 2026, 21:52 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q Rev $165.2M >BULL

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q EPS 1c >BULL

4. märts 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. märts 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4. märts 2026, 21:40 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:36 UTC

Uudisväärsed sündmused

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4. märts 2026, 21:27 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4. märts 2026, 21:16 UTC

Tulu

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q EPS $1.50 >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Net $7.35B >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Rev $19.31B >AVGO

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

885.11% tõus

12 kuu keskmine prognoos

Keskmine 4.63 USD 885.11%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

333 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.